Yonsei Med J.  2016 Jan;57(1):272-273. 10.3349/ymj.2016.57.1.272.

Pulmonary Sarcoidosis Induced by Adalimumab: A Case Report and Literature Review

• Sim JK
• Lee SY
• Shim JJ
• Kang KH

• KMID: 2466382
• DOI: http://doi.org/10.3349/ymj.2016.57.1.272

Abstract

No abstract available.

Figure

• 

  Fig. 1 (A) There are consolidation and clustered nodules at both upper lobes. (B) Multiple non-caseous granulomas are located along lymphatic route with parenchymal inflammation (H&E, original magnification ×200).

Reference

1. Pueringer RJ, Schwartz DA, Dayton CS, Gilbert SR, Hunninghake GW. The relationship between alveolar macrophage TNF, IL-1, and PGE2 release, alveolitis, and disease severity in sarcoidosis. Chest. 1993; 103:832–838.

2. Ziegenhagen MW, Rothe ME, Zissel G, Müller-Quernheim J. Exaggerated TNFalpha release of alveolar macrophages in corticosteroid resistant sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2002; 19:185–190.

3. Baughman RP, Drent M, Kavuru M, Judson MA, Costabel U, du Bois R, et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med. 2006; 174:795–802.

4. Sweiss NJ, Noth I, Mirsaeidi M, Zhang W, Naureckas ET, Hogarth DK, et al. Efficacy Results of a 52-week Trial of Adalimumab in the Treatment of Refractory Sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2014; 31:46–54.

5. Dinarello CA. Differences between anti-tumor necrosis factor-alpha monoclonal antibodies and soluble TNF receptors in host defense impairment. J Rheumatol Suppl. 2005; 74:40–47.

6. Eishi Y, Suga M, Ishige I, Kobayashi D, Yamada T, Takemura T, et al. Quantitative analysis of mycobacterial and propionibacterial DNA in lymph nodes of Japanese and European patients with sarcoidosis. J Clin Microbiol. 2002; 40:198–204.

7. van der Stoep D, Braunstahl GJ, van Zeben J, Wouters J. Sarcoidosis during anti-tumor necrosis factor-alpha therapy: no relapse after rechallenge. J Rheumatol. 2009; 36:2847–2848.